Nexalin Technology (NXL) EBT Margin Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) EBT Margin Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -419.00 |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 110.00 |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -300.00 |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 507.00 |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -287.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 233.00 |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 772.00 |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -464.00 |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 584.00 |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | -918,039.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -918,039.00 |
| Dec 31, 2025 | 904,268.00 |
| Sep 30, 2025 | -574,705.00 |
| Jun 30, 2025 | 254,119.00 |
| Mar 31, 2025 | -351,449.00 |
| Dec 31, 2024 | -662,377.00 |
| Sep 30, 2024 | 273,146.00 |
| Jun 30, 2024 | -246,681.00 |
| Mar 31, 2024 | 111,822.00 |
| Dec 31, 2023 | -189,351.00 |
| Sep 30, 2023 | -947,108.00 |
| Jun 30, 2023 | -220,668.00 |
| Mar 31, 2023 | -232,737.00 |
| Dec 31, 2022 | 57,518.00 |
| Sep 30, 2022 | 320,075.00 |